Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib and GSK2141795 in advanced triple negative breast cancer
NCT01964924Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2013
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of uprosertib, trametinib in triple-negative breast cancer (TNBC), sponsored by National Cancer Institute. Started Oct 2013; status: completed.
02
Drugs
uprosertibtrametinib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT01964924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01964924.